A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation.

Outcomes reported in this study are favourable and comparable to those reported previously. The addition of rituximab did not appear to have improved outcomes in this series, although a significant proportion of patients were able to avoid chemotherapy.